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Abstract 
Studies have indicated that ApoB/ApoA-I ratio is significantly associated with MetS and IR. This study was 
designedto assess the optimal cutoff values of ApolipoproteinB/ApolipoproteinA-I (ApoB/ApoA-I) ratio for the 
diagnosis of metabolic syndrome  and insulin resistance (IR) in the population of Georgia. The subjects were 
1522 Georgians of Caucasian origin aged 18-80 (653 women and 869 men) without diabetes mellitus. MetS was 
diagnosed using the updated ATP-III definition of the metabolic syndrome. Receiver operating characteristics 
(ROC) curve analysis was performed to calculate the cutoff values. ROC analysis showed that areas under the 
curve (AUCs) of ApoB/ApoA-I ratio for the detection of MetS were 0.786±0.025 (95%CI: 0.737-0.834) in 
women and 0.815±0.017 (95%CI: 0.782-0.847) in men. AUCs of ApoB/ApoA-I ratio for the diagnosis of IR 
were 0.887±0.019 (95%CI: 0.850-0.924) in women and 0.816±0.022 (95%CI: 0.773-0.860) in men.  After 
adjustment for age, MetS components and low-density lipoprotein cholesterol, odds ratios according to the 
determined cutoff values of ApoB/ApoA-I ratio were: for MetS – 1.75 in women and 1.18 in men; for IR – 
13.61 in women and 7.75 in men.  
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Study showed that in the population of Georgia optimal cutoff values of ApoB/ApoA-I ratio for the detection of 
MetS were 0.74 in women and 0.82 in men; for the detection of IR these values were 0.82 in women and 0.98 in 
men. 
Keywords: ApoB/ApoA-I ratio; cutoff value; insulin resistance; metabolic syndrome  
1. Introduction  
The prevalence of metabolic syndrome and insulin resistance (IR) is increasing worldwide [7, 18, 20, 23, 34]. 
MetS is a condition that promotes atherogenesis and increases the risk of cardiovascular disease and diabetes 
mellitus (DM) [10, 12, 14, 19, 24] by a grouping of multiple risk factors such as central obesity, arterial 
hypertension (AH), glucose intolerance, elevated triglycerides  and low high-density lipoprotein cholesterol 
(HDL-C) [2]. These factors are associated with insulin resistance (IR), which is considered to be the underlying 
shared pathophysiological disturbance [12, 24, 38]. So, determining additional simple markers for the detection 
of MetS and IR can help better identify patients who are at high risk for cardiovascular disorders and DM. IR 
can be measured by Homeostasis model assessment of insulin resistance (HOMA-IR), Quantitative Insulin 
Sensitivity Check Index (QUICKI) and other indices [5, 6, 21, 26-28, 35]. MetS is diagnosed by a combination 
of various clinical and laboratory criteria, according to different definitions [1-3].Recent studies have indicated 
that ApoB/ApoA-I ratio is significantly associated with MetS components and IR [9, 22, 29, 30, 33, 37, 39]. 
Serum concentration of ApolipoproteinA-I (ApoA-I), which is the protein covering the HDL particle, reflects 
the number of anti-atherogenic particles. Serum concentration of ApoB yields the number of atherogenic 
particles [11, 32].  
 There are several reports, determining the optimal cutoff value of ApoB/ApoA-I ratio for the detection of MetS 
and IR [15, 16, 25, 36]. There is no Georgian report available about this subject. So we conducted this study to 
assess the value of ApoB/ApoA-I ratio for the detection of MetS and IR in the population of Georgia. 
2. Materials and Methods 
Details about the materials and methods (Subjects, Anthropometric measurements and laboratory data, MetS 
and IR definition) are described elsewhere [22].  
2.1 Subjects 
We analyzed 1522 Georgians of Caucasian origin, who had visited the clinics for a related health checkup 
between 2012 and 2013. Subjects were men and non-pregnant women aged ≥ 18 years, < 80 years (mean age = 
45 years, 653 women and 869 men). Informed consent was obtained from every subject.  
2.2 Anthropometric measurements and laboratory data 
Anthropometric measurements were done using standardized techniques and equipment. Insulin sensitivity 
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index was determined using the updated computer homeostasis model assessment (HOMA2-IR) index. Venous 
blood samples were drawn after a minimum of 8 h of fasting. ApoB and ApoA-I levels were measured by the 
immunoturbidimetric assay with Roche Diagnostics kit, using Roche/Hitachi C311 analyzer. Other laboratory 
measurements were done using HUMAN Diagnostic Kit (GERMANY).  
2.3 Metabolic syndrome definition 
The updated ATP-III definition of MetS[13] was used when any three or more criteria were present: waist 
circumference (WC) ≥ 102cm in men and ≥ 88cm in women; impaired fasting glucose - fasting blood glucose 
(FG) of ≥ 5.6 mmol/l (100mg/dl); systolic blood pressure (SP) ≥ 130mmHg and/or diastolic blood pressure (DP) 
≥ 85mmHg or treatment of previously diagnosed hypertension; fasting levels of triglycerides  ≥ 1.7 mmol/l 
(150mg/dl) or treatment for this abnormality; fasting high-density lipoprotein cholesterol (HDL-C) < 1.03 
mmol/l (40mg/dl) for men and < 1.30 mmol/l (50mg/dl) for women or treatment for this abnormality 
 
2.4 Statistical analysis 
 
All the analysis were performed using IBM SPSS Statistics for Windows (version 22.0), except for ROC curve 
analysis, which was done with MedCalc Software bvba (version 11.4.2). 
IR was defined as the gender-specific upper quartile ofHOMA2-IR (≥ 2.3 for women and ≥ 2.9 for men) and 
insulin sensitive (IS) as the remaining three quartiles. We used the Mann-Whitney U test to compare related data 
between sexes, between subjects with vs. without IR.  
 
Figure 1: Receiver operating characteristic (ROC) curve of ApoB/ApoA-I ratio for MetS in females. 
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To assess the utility of ApoB/ApoA-I ratio as marker for MetS and IR, we built gender-specific receiver 
operator characteristic (ROC) curves and calculated the areas under the curve (AUC) and cut-off values of 
ApoB/ApoA-I ratio for the detection of MetS and IR in both sexes. 
A binary logistic regression analysis was carried out to assess the association of determined cutoff values of 
ApoB/ApoA-I ratio with MetS and IR as definitions (after adjustment for age, MetS components and LDL-C). 
For all tests performed, a p value of less than 0.05 was considered significant. 
 
3. Results 
 
Main characteristics between sexes and between subjects with vs. without IR are described elsewhere [22].  
To assess the predictive value of ApoB/ApoA-I ratio for MetS and IR, we analyzed the ROC curves of 
ApoB/ApoA-I ratio (Figure 1-4).  
ROC analysis results for both sexes are shown in Table 1. AUCs of ApoB/ApoA-I ratio for the detection of 
MetS were: 0.786 in women and 0.815 in men; AUCs for the detection of IR were: 0.887 in women and 0.816 in 
men. 
 
 
Figure 2: Receiver operating characteristic (ROC) curve of ApoB/ApoA-I ratio for MetS in males. 
 
The optimal cutoff value of ApoB/ApoA-I ratio for the diagnosis of MetS was 0.74 (with sensitivity of 77.8% 
and specificity of 83.6%) in women and 0.82 (with sensitivity of 78.7% and specificity of 79.1%) in men(Figure 
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5). The optimal cutoff value of ApoB/ApoA-I ratio for the diagnosis of IR was 0.82 (with sensitivity of 87.7% 
and specificity of 88.8%) in women and 0.98 (with sensitivity of 74.8% and specificity of 88.3%) in men 
(Figure 6). 
 
 
 
Figure 3: Receiver operating characteristic (ROC) curve of ApoB/ApoA-I ratio for IR in females. 
 
 
Logistic regression models demonstrated that after adjustment for age, MetS components and LDL-C, 
determined cutoff values of ApoB/ApoA-I ratio were associated significantly with MetS: OR = 1.75 in women 
and 1.18 in men and with IR: OR = 13.61 in women and 7.75 in men (all p <.05) (Table 2). 
 
4. Discussion 
 
The prevalence of IR and MetS is increasing worldwide [7, 8, 18, 20, 34]. Many studies have indicated that 
ApoB/ApoA-I ratio is significantly associated with MetS components and IR [4, 9, 22, 29-31, 33, 37, 39]. But 
fewer studies (predominantly in Asian ethnicities) have focused on the optimal cutoff values of ApoB/ApoA-I 
ratio for the diagnosis of MetS and IR. The authors in [25] in the ATTICA study investigated the ApoA-I, ApoB 
and ApoB/ApoA-I ratio in relation to the MetS. Using the ROC curve analysis, they found that  ApoB/ApoA-I 
ratio was the best diagnostic marker of MetS and the optimal  discriminating cutoff value of this ratio was 0.72 
(with sensitivity – 74% and specificity – 67%). The authors in [36] investigated 160 Chinese adolescent women 
with polycystic ovary syndrome. They concluded that ApoB/ApoA-I ratio was a good predictive marker of 
MetS and pre-MetS with a threshold value of ApoB/ApoA-I ratio of 0.63 for MetS (with sensitivity – 86.2% and 
specificity – 79.4%) and 0.58 for pre-MetS. 
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The authors in [16] investigated 10.940 Korean subjects who participated in a routine health screening 
examination. They found that the optimal ApoB/ApoA-I ratio cutoff value for the detection of MetS was 0.65 
(with sensitivity – 63.5% and specificity – 61.3%) in men, and 0.62 (with sensitivity – 67.9% and specificity – 
61.9%) in women. 
 
 
 
Figure 4: Receiver operating characteristic (ROC) curve of ApoB/ApoA-I ratio for IR in males 
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Figure 5: Dot diagram for cut-off values of ApoB/ApoA-I ratio for the detection of MetS in women and men 
 
Table 1: Receiver operating characteristic (ROC) curve analysis of ApoB/ApoA-I ratio for MetS (a) and IR (b) 
in both sexes. 
(a) 
Gender AUC Std. Error Asymptotic Sig. 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
      
Female .786 .025 .000 .737 .834 
Male .815 .017 .000 .782 .847 
 
(b) 
Gender AUC Std. Error Asymptotic Sig. 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
      
Female .887 .019 .000 .850 .924 
Male .816 .022 .000 .773 .860 
AUC – Area under the curve; MetS – metabolic syndrome; IR – insulin resistance 
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Figure 6: Dot diagram for cut-off values of ApoB/ApoA-I ratio for the detection of IR in women and men 
 
 
The authors in [17] performed a retrospective study of 41.821 Korean adults who participated in a routine health 
screening examination. They found that the optimal cutoff value of ApoB/ApoA-I ratio for the detection of 
MetS was 0.64 (with sensitivity – 74.1% and specificity – 67.4%) in women and 0.72 (with sensitivity – 64.3% 
and specificity – 59%) in men. AUCs of ApoB/ApoA-I ratio for IR was 0.58 in men and 0.62 in women. 
In this study AUCs of ApoB/ApoA-I ratio for MetS and IR were significantly higher in women than in men, 
indicating that the predictive value of ApoB/ApoA-I ratio for the detection of MetS and IR was higher in 
women than in men. In our study this tendency was found only for IR (AUCs: 0.89 in women and 0.816 in 
men). The authors in [15] investigated 8.120 subjects from the China Health Nutrition Survey in 2009. They 
found that ApoB/ApoA-I ratio higher than 0.85 in men and 0.80 in women may be a promising and convenient 
marker for MetS.  
Our study showed that AUCs of ApoB/ApoA-I ratio for IR were significantly higher than these for MetS, 
indicating that the predictive value of ApoB/ApoA-I ratio for the detection of IR was higher than that for MetS 
in both sexes (p <.0001).  
 
Further studies in other ethnicities are needed to confirm these findings providing ethnic cutoff differences of 
ApoB/ApoA-I ratio for the prediction of MetS and IR.  
 
5. Study Limitations 
This study has several limitations. The subjects were not a general population but visitors to the clinic. IR was 
diagnosed using surrogate marker (HOMA2-IR) of IR and not the “gold standard” (euglycemic clamp), although 
they correlate well. 
 
Table 2: Odds ratios for MetS and IR (as definitions) according to the determined cutoff values of ApoB/ApoA-
I ratio after adjustment for age, MetS components and LDL-C in both sexes 
 
 
ApoB/ApoA-I Ratio
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 Women Men 
 OR 95% CI P value OR 95% CI p 
MetS as difinition 1.75 .78 - 3.90 .026 1.18 .58 – 2.40 .047 
IR as definition 13.61 6.49 – 28.54 < .0001 7.75 4.30 - 13.97 < .0001 
OR odds ratio, CI confidence interval, MetS Metabolic syndrome, IR Insulin resistant, defined as the gender-
specific upper quartile ofHOMA2-IR ≥ 2.3 for women and ≥ 2.9 for men, LDL-C low-density lipoprotein 
cholesterol, NS nonsignificant 
 
6. Conclusion 
In the population of Georgia the optimal cutoff values of ApoB/ApoA-I ratio for the detection of MetS were 
0.74 in women and 0.82 in men; for the detection of IR these values were 0.82 in women and 0.98 in men. 
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